Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
20 Juillet 2023 - 10:45PM
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage
immuno-oncology company, today announced two key management
promotions, as well as the addition of two new members to its
leadership team. Joseph Cappello, Ph.D., who previously served as
the Company’s Vice President of Pharmaceutical Development, has
been promoted to Chief Technical Officer. Tony Yu, Ph.D., formerly
the Company’s Vice President of Clinical Trial Operations, has been
promoted to Senior Vice President of Clinical Development. Ralph
Smalling, MS has joined the Company as Head of Regulatory and
Caroline Jewett has joined the Company as Head of Quality.
Dr. Cappello has served as Vice President of
Pharmaceutical Development since November 2012 and General Manager
of Manufacturing Facility since September 2018. Dr. Cappello has
over 30 years of experience in pharmaceutical and medical device
development, research and development, good manufacturing practice,
clinical study design and management and academic research.
Dr. Yu has served as the Vice President of
Clinical Trial Operations since January 2010, and was the first
employee of Genelux in 2002. Dr. Yu has published more than 40
research articles in peer-reviewed journals and holds more than 20
granted U.S. patents. Additionally, Dr. Yu is a member of the
American Society of Clinical Oncology.
Mr. Smalling, with expertise in all aspects of
regulatory development, has over 40 years of experience
in the biopharmaceutical industry. Previously, he served at Amgen
Inc. (“Amgen”) in positions of increasing responsibility where he
held the title of Vice President of Regulatory Affairs and
International Safety. Under his leadership, Amgen obtained
numerous marketing authorizations (including for
blockbusters EPOGEN® and NEUPOGEN®), supplemental
approvals and orphan drug designations in the United States,
European Union, Canada and Australia.
Ms. Jewett is a quality professional with over
35 years of experience in the biopharmaceutical industry. From 1987
to 2014, Ms. Jewett held positions of increasing responsibility at
Amgen, including Site Head for Clinical Quality, Executive Director
for Corporate Quality and Plant Manager for both commercial and
clinical manufacturing facilities. She also served as the
Inflammation Therapeutic Area Head for Operations at Amgen.
“Joe and Tony's promotions are truly
well-deserved, a testament to the invaluable contributions they
have individually made to the success of Genelux over our long
history” said Thomas Zindrick, President, Chairman and CEO of
Genelux. “We are also delighted to welcome Ralph and Caroline as
new additions to the Genelux Team. They are longstanding
consultants to our company, with a wealth of industry experience in
successful product approval and life cycle management. I look
forward to them continuing to make significant contributions as we
strive to create an exceptional team. With our Phase 3 OnPrime
trial underway and the possibility of a potential biologics license
application, we are dedicated to positioning ourselves with
accomplished leaders in key roles, ensuring a path of impactful
success.”
About Genelux
CorporationGenelux is a late clinical-stage
biopharmaceutical company focused on developing a pipeline of
next-generation oncolytic immunotherapies for patients suffering
from aggressive and/or difficult-to-treat solid tumor types. The
Company's most advanced product candidate, Olvi-Vec (olvimulogene
nanivacirepvec), is a proprietary, modified strain of the vaccinia
virus (VACV), a stable DNA virus with a large engineering capacity.
Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a
multi-center, randomized, open-label Phase 3 registrational trial
evaluating the efficacy and safety of Olvi-Vec in patients with
platinum-resistant/refractory ovarian cancer. The core of Genelux'
discovery and development efforts revolves around the company's
proprietary CHOICE™ platform from which the Company has developed
an extensive library of isolated and engineered oncolytic vaccinia
virus immunotherapeutic product candidates, including Olvi-Vec. For
more information, please visit www.genelux.com and follow us on
Twitter @Genelux_Corp and on LinkedIn.
Forward-Looking StatementsThis
release contains “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
“Forward-looking statements” describe future expectations, plans,
results, or strategies and are generally preceded by words such as
“believes,” “anticipates,” “expect,” “may,” “plan” or “will”.
Forward-looking statements in this release include, but are not
limited to, statements related to the potential contributions that
will be made by the Company’s team members, the possibility of a
potential biologics license application, and our leadership team
ensuring a path of impactful success. Such statements are subject
to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those
projected in the forward-looking statements. These and other risks
are identified under the caption “Risk Factors” in Genelux’ filings
with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. Genelux does not
undertake any obligation to publicly update any forward-looking
statements, whether as a result of the receipt of new information,
the occurrence of future events or otherwise.
Investor and Media Contacts
Ankit Bhargava, MDAllele Communications,
LLCgenelux@allelecomms.com815.721.4912
Source: Genelux Corporation
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024